OpenCareby Vivonco
Search/
Talk to us Review a case
Menu
Skip to content
No. 39 · Tuesday, November 17, 2026

Carfilzomib-based treatment improves outcomes in multiple myeloma

  1. Carfilzomib-based treatment improves outcomes in multiple myeloma
  2. Genome sequencing may guide treatment across solid cancers
  3. Sickle cell mice showed blood changes linked to acute myeloid leukemia
Read this first · Phase II trial · myeloma

Carfilzomib-based treatment improves outcomes in multiple myeloma

In a phase 2 trial, people with newly diagnosed multiple myeloma who could have a transplant received a carfilzomib-based combination with or without a transplant. Cancer growth was delayed for 98 months with a transplant, versus 70 months without one.

“In conclusion, long-term follow-up confirms the high effectiveness of KRd-ASCT and KR maintenance.”

Why it matters. People with newly diagnosed multiple myeloma who can have a transplant may have more time before their cancer grows. A larger trial usually comes before approval.

Blood, 16 Nov 2026 · Phase II human clinical trial Worth sharing · Share on X · Email a friend
Research

Genome sequencing may guide treatment across solid cancers

A retrospective analysis across solid cancers found that whole-genome sequencing can identify possible targets for targeted drugs. Trials are needed to learn whether these findings can expand treatment beyond current cancer-specific uses.

“Our findings support comprehensive whole-genome sequencing assessment of cancers irrespective of tumour type.”

Why it matters. People with solid cancers may one day get targeted drugs chosen from whole-genome sequencing results. It studied patient records rather than testing a treatment.

The Lancet Oncology, 16 Nov 2026 · Human observational study
Lab stage · acute myeloid leukaemia

Sickle cell mice showed blood changes linked to acute myeloid leukemia

Researchers tracked blood changes in sickle cell mice and found more abnormal blood-cell growth and cancer-linked cell clones. Repeated stem cell transplants increased the number of these clones.

“Our study provides insights into a mechanism underlying increased risk of HM in this non-malignant hematological disorder, and suggests that early intervention with curative therapies may circumvent this risk.”

Why it matters. This could one day help people with sickle cell disease avoid blood cancers linked to abnormal blood-cell growth. This lab work is years from patients.

Blood, 16 Nov 2026 · Translational research (lab work plus patient samples)

Deals and stopped trials

India

New trials

Worth watching